Results 211 to 220 of about 665,029 (266)
Some of the next articles are maybe not open access.

Safety Profile of Quinolones

European Urology, 1990
Tolerability data from reports to Federal Drug Authorities, information from drug companies, medical literature, and personal experience are cited. Tolerability data regarding norfloxacin were derived from more than 31,000 patients in a phase IV study; ofloxacin from more than 14,000 patients in a phase IV study; and ciprofloxacin from more than 8,000 ...
P M, Shah, R, Mulert
openaire   +2 more sources

Safety profile of the triptans

Expert Opinion on Drug Safety, 2003
The triptans are 5-HT(1B/1D) agonists used as migraine and cluster-specific agents. Seven are in commercial use worldwide; in order of release these are sumatriptan, zolmitriptan, rizatriptan, naratriptan, almotriptan, frovatriptan and eletriptan. Sumatriptan has been in clinical use since 1991, and although postmarketing studies have stimulated much ...
Stewart J, Tepper, David, Millson
openaire   +2 more sources

The safety profile of the fluoroquinolones

Clinical Therapeutics, 2000
Premarketing trials showed the fluoroquinolone agents to have a favorable side-effect profile, with treatment-related adverse events comprising gastrointestinal, central nervous system, and dermatologic effects that were generally mild and reversible on cessation of treatment.
J, Bertino, D, Fish
openaire   +2 more sources

Safety profile of gemcitabine

Anti-Cancer Drugs, 1995
This paper reviews the toxicity profile of gemcitabine in a large group of patients (up to 790) from pivotal phase II studies, in which the drug was given intravenously as a 30 min infusion, in a schedule once a week for 3 weeks followed by a week of rest.
M, Tonato, A M, Mosconi, C, Martin
openaire   +2 more sources

Safety profile of cefodizime

Infection, 1992
The results of animal toxicology studies with cefodizime (CDZ) showed no reason for concern with respect to drug safety. Renal tolerance of CDZ proved to be better than that observed with other cephalosporins; furthermore, CDZ had no adverse effects on spermatogenesis, fertility or embryonic development.
openaire   +2 more sources

Safety Profile of Cefprozil

Clinical Infectious Diseases, 1992
The clinical and laboratory safety of cefprozil was analyzed with data from 4,227 patients who received the drug in North American and European clinical efficacy trials. Of these patients, 3,016 adults and children received capsules or tablets, while 1,211 patients (mostly children) were treated with cefprozil suspension.
R B, Wilber   +5 more
openaire   +2 more sources

Safety Profile of Bevantolol

Angiology, 1986
Double-blind and long-term open-label studies have demonstrated a remark ably favorable safety profile for bevantolol. The drug was associated with a low incidence of adverse experiences similar to that observed with placebo. The adverse experiences were mostly mild to moderate and of the types found previ ously for other beta-blocking drugs.
openaire   +2 more sources

Safety profile of cefixime

The Pediatric Infectious Disease Journal, 1987
The clinical and laboratory safety of cefixime based on analysis of data from 1575 adults (1118 treated daily and 457 treated twice a day) and 615 children (299 treated daily and 316 treated twice a day) in studies of urinary tract and lower and upper respiratory tract infections (including otitis media) is reviewed.
F P, Tally   +3 more
openaire   +2 more sources

Safety profile of perindopril

The American Journal of Cardiology, 2001
Approximately 25% of US adults have high blood pressure (BP). Selection of effective and safe antihypertensive therapy for these individuals is an important health-care priority. High BP can be treated with a wide range of antihypertensive agents from a number of different classes.
openaire   +2 more sources

Safety profile of celiprolol

American Heart Journal, 1988
Celiprolol hydrochloride is a highly cardioselective beta1-adrenergic antagonist with a unique pharmacologic profile. The adverse experience safety data derived from 18 double-blind trials (n = 2884) were evaluated. The results demonstrated a wide margin of safety for celiprolol over the recommended dosage range of 200 to 600 mg once daily.
openaire   +2 more sources

Home - About - Disclaimer - Privacy